Anzeige
Mehr »
Freitag, 08.08.2025 - Börsentäglich über 12.000 News
Das Kupferangebot bricht ein - und dieser neue Fund kommt genau zur richtigen Zeit
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D4GD | ISIN: US02155X2053 | Ticker-Symbol: PBN0
Siehe auch ALTERITY THERAPEUTICS LIMITED
NASDAQ
07.08.25 | 21:23
5,250 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
ALTERITY THERAPEUTICS LIMITED ADR Chart 1 Jahr
5-Tage-Chart
ALTERITY THERAPEUTICS LIMITED ADR 5-Tage-Chart

Aktuelle News zur ALTERITY THERAPEUTICS LIMITED ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer-
MoALTERITY THERAPEUTICS LIMITED: Response to ASX Query Letters-
31.07.ALTERITY THERAPEUTICS LIMITED: Updated Corporate Presentation-
ALTERITY THERAPEUTICS LIMITED ADR Aktie jetzt für 0€ handeln
30.07.ALTERITY THERAPEUTICS LIMITED: Appendix 4C - Q4 FY25 Quarterly Cash Flow Report112Highlights Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA)Reported positive topline data from open-label Phase 2 clinical trial of ATH434 in MSAPresented...
► Artikel lesen
30.07.ALTERITY THERAPEUTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report2
28.07.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer1
28.07.ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy216- ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms - - Neuroimaging Biomarkers Showed Target Engagement and Slowed Brain Atrophy...
► Artikel lesen
28.07.Alterity Therapeutics Confirms Effectiveness of ATH434 Drug Against Advanced MSA1
28.07.Alterity Therapeutics Announces Positive Results from ATH434 Phase 2 Trial in Multiple System Atrophy6
28.07.ALTERITY THERAPEUTICS LIMITED: Positive ATH434 Results from Open-Label Phase 2 Trial in MSA-
28.07.ALTERITY THERAPEUTICS LIMITED: Change in substantial holding1
24.07.ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study4
24.07.ALTERITY THERAPEUTICS LIMITED: Peer-Reviewed Publication on Novel MRI Endpoint from bioMUSE1
21.07.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer1
21.07.ALTERITY THERAPEUTICS LIMITED: Application for quotation of securities - ATH-
17.07.ALTERITY THERAPEUTICS LIMITED: Application for quotation of securities - ATH7
14.07.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer2
14.07.ALTERITY THERAPEUTICS LIMITED: Response to ASX Price Query-
07.07.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer1
06.07.ALTERITY THERAPEUTICS LIMITED: Change in substantial holding-
Weiter >>
59 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1